Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population.
BACKGROUND
Although implantable cardioverter-defibrillator (ICD) therapy reduces mortality in moderately symptomatic heart failure patients with an ejection fraction <or=35%, many such patients do not require ICD shocks over long-term follow-up.


RESULTS
Using a modification of a previously validated risk prediction model based on routine clinical variables, we examined the relationship between baseline predicted mortality risk and the relative and absolute survival benefits of ICD treatment in the primary prevention Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). In the placebo arm, predicted 4-year mortality grouped into 5 equal-sized risk groups varied from 12% to 50% (c statistic=0.71), whereas the proportion of SCD in those same risk groups decreased from 52% to 24% of all deaths. ICD treatment decreased relative risk of SCD by 88% in the lowest-risk group versus 24% in the highest-risk group (P=0.009 for interaction) and decreased relative risk of total mortality by 54% in the lowest-risk group versus no benefit (2%) in the highest-risk group (P=0.014 for interaction). Absolute 4-year mortality reductions were 6.6%, 8.8%, 10.6%, 14.0%, and -4.9% across risk quintiles. In highest-risk patients (predicted annual mortality >20%), no benefit of ICD treatment was seen. Projected over each patient's predicted lifespan, ICD treatment added 6.3, 4.1, 3.0, 1.9, and 0.2 additional years of life in the lowest- to highest-risk groups, respectively.


CONCLUSIONS
A clinical risk prediction model identified subsets of moderately symptomatic heart failure patients in SCD-HeFT in whom single-lead ICD therapy was of no benefit and other subsets in which benefit was substantial.
Levy
Wayne C
WC
Division of Cardiology, University of Washington, Box 356422, 1959 NE Pacific St, Seattle, WA 98195, USA. levywc@u.washington.edu
Lee
Kerry L
KL
Hellkamp
Anne S
AS
Poole
Jeanne E
JE
Mozaffarian
Dariush
D
Linker
David T
DT
Maggioni
Aldo P
AP
Anand
Inder
I
Poole-Wilson
Philip A
PA
Fishbein
Daniel P
DP
Johnson
George
G
Anderson
Jill
J
Mark
Daniel B
DB
Bardy
Gust H
GH
D000328:Adult; D000638:Amiodarone / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D016757:Death, Sudden, Cardiac / Q000209:etiology* / Q000517:prevention & control*; D017147:Defibrillators, Implantable; D005260:Female; D006333:Heart Failure / Q000150:complications* / Q000401:mortality / Q000628:therapy*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D011322:Primary Prevention / Q000379:methods*; D012306:Risk
D000889:Anti-Arrhythmia Agents; D000638:Amiodarone
Lancet. 2003 Jul 5;362(9377):7-13
12853193
Int J Epidemiol. 1998 Oct;27(5):885-9
9839748
J Card Fail. 2005 Mar;11(2):91-8
15732027
Circulation. 2007 Jul 24;116(4):392-8
17620506
Eur J Heart Fail. 2009 Mar;11(3):256-63
19164422
N Engl J Med. 2005 Jan 20;352(3):225-37
15659722
JAMA. 2003 Nov 19;290(19):2581-7
14625335
Circulation. 2005 Sep 20;112(12):e154-235
16160202
Circulation. 2008 May 27;117(21):e350-408
18483207
J Am Coll Cardiol. 2007 Sep 18;50(12):1150-7
17868806
Circulation. 2006 Mar 21;113(11):1424-33
16534009
Am Heart J. 2008 Feb;155(2):339-47
18215606
Am Heart J. 2006 Oct;152(4):724-30
16996848
Am J Geriatr Cardiol. 2004 Sep-Oct;13(5):252-60
15365288
N Engl J Med. 2001 Dec 6;345(23):1667-75
11759645
N Engl J Med. 1988 Jun 30;318(26):1728-33
3374545
Circ Cardiovasc Qual Outcomes. 2009 Jan;2(1):16-24
20031808
Circulation. 2008 Nov 11;118(20):2022-8
18955671
J Am Coll Cardiol. 2007 Jun 26;49(25):2408-15
17599603
J Am Coll Cardiol. 2008 Jan 22;51(3):288-96
18206738
Circ Arrhythm Electrophysiol. 2008 Oct;1(4):240-9
19169382
N Engl J Med. 1996 Oct 10;335(15):1107-14
8813041